Lorito, N.; Bacci, M.; Smiriglia, A.; Mannelli, M.; Parri, M.; Comito, G.; Ippolito, L.; Giannoni, E.; Bonechi, M.; Benelli, M.;
et al. Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib+. Cells 2020, 9, 668.
https://doi.org/10.3390/cells9030668
AMA Style
Lorito N, Bacci M, Smiriglia A, Mannelli M, Parri M, Comito G, Ippolito L, Giannoni E, Bonechi M, Benelli M,
et al. Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib+. Cells. 2020; 9(3):668.
https://doi.org/10.3390/cells9030668
Chicago/Turabian Style
Lorito, Nicla, Marina Bacci, Alfredo Smiriglia, Michele Mannelli, Matteo Parri, Giuseppina Comito, Luigi Ippolito, Elisa Giannoni, Martina Bonechi, Matteo Benelli,
and et al. 2020. "Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib+" Cells 9, no. 3: 668.
https://doi.org/10.3390/cells9030668
APA Style
Lorito, N., Bacci, M., Smiriglia, A., Mannelli, M., Parri, M., Comito, G., Ippolito, L., Giannoni, E., Bonechi, M., Benelli, M., Migliaccio, I., Malorni, L., Chiarugi, P., & Morandi, A.
(2020). Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib+. Cells, 9(3), 668.
https://doi.org/10.3390/cells9030668